Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

Clinical Pharmacokinetics

Volumn 40, Issue 5, 2001, Pages 327-341

  Burman, W J ^a,b   Gallicano, K ^c   Peloquin, C ^d  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIINFECTIVE AGENT; CLOFAZIMINE; CYTOCHROME P450 3A; KETOCONAZOLE; PASER; PROTEINASE INHIBITOR; RANITIDINE; RIFABUTIN; RIFAMATE; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RIFATER;

ANTIBACTERIAL ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG PROTEIN BINDING; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; HUMAN; HYPERSENSITIVITY; MYCOBACTERIUM; NAUSEA; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; TOXIC HEPATITIS; TUBERCULOSIS;

EID: 0034972610     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140050-00002     Document Type: Review

References (161)

1. Controlled trial of four short-course (6-month) regimens of chemotherapy for the treatment of pulmonary tuberculosis
2. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis
3. Short-course chemotherapy for tuberculosis with largely twice-weekly isoniazid-rifampin
4. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: A twice-weekly, directly observed, and cost-effective regimen
5. Isoniazid for pulmonary tuberculosis in Singapore: The results up to 30 months
6. Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons: Ah international randomized trial
7. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized trial
8. Lessons learned from animal models of osteomyelitis
9. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants
10. Chronic osteomyelitis caused by Staphylococcus aureus: Controlled clinical trials of nafcillin therapy and nafcillin-rifampin therapy
11. Oral antibiotic treatment of right-sided staphylocccal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy
12. Determination of in vitro susceptibility of mycobacteria to ansamycin
13. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-I associated tuberculosis: A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis
14. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis
15. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects
16. Clinical pharmacokinetics of rifampicin
17. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate
18. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: A phase I study
19. Single and multiple dose pharmacokinetics of rifapentine in man: Part II
20. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: Initial report
21. TBTC Study 22 (rifapentine trial): Preliminary results in HIV-negative patients
22. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice
23. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: Part I
24. Pharmacokinetics of oral and intravenous rifampicin during chronic administration
25. Clinical pharmacokinetics of rifabutin
26. Rifabutin absorption in humans: Relative bioavailability and food effect
27. Comparison of Chinese and Western rifapentines and improvement by prior taking of various meals
28. Pharmacokinetic study of intravenous rifampin
29. Pharmacokinetics of rifabutin
30. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids
31. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids
32. A controlled comparison of two fully supervised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis
33. Ranitidine-rifampin interaction
34. A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients
35. Rifampin plus isoniazid, rifampicin plus PAS, and isoniazid plus PAS in the initial treatment of pulmonary tuberculosis: A controlled multicenter trial
36. Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: Adsorption of rifampicin by an excipient, bentonite
37. Interaction of ketoconazole with rifampicin and isoniazid
38. Effect of clofazimine and dapsone on rifampin pharmacokinetics in multibacillary and paucibacillary leprosy cases
39. The effect of clofazimine on the pharmacokinetics of rifampin and dapsone in leprosy
40. Failure of ketoconazole treatment of Blastomyces dermatitidis due to interaction of isoniazid and rifampin
41. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients
42. Bioavailability of rifampicin capsules
43. Rifampicin raw material characteristics and their effect on bioavailability
44. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis
45. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy
46. Fixed-dose combination formulations for tuberculosis treatment
47. Effect of preparation method and storage on rifampin concentration in suspensions
48. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong
49. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease
50. Low antituberculosis drug concentrations in patients with AIDS
51. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease
52. Reduced plasma concentrations of antituberculous drugs in patients with HIV infection
53. Malabsorption of antituberculosis medications by a patient with AIDS
54. Drug malabsorption and resistant tuberculosis in HIV-infected patients
55. Risk factors for rifampin mono-resistant tuberculosis
56. Does AIDS impair the absorption of antituberculosis agents?
57. The pharmacokinetics of oral rifampicin in AIDS patients
58. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS and diarrhea
59. TB drug absorption study: Serum rifampin level and CD4 counts in HIV-infected TB patients
60. AIDS and TB drug absorption
61. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection
62. HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS
63. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection
64. Lack of effect of concomitant zidovudine on rifabutin pharmacokinetics in patients with AIDS-related complex
65. Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients
66. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers
67. Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome
68. Rifampin-monoresistant tuberculosis in New York City, 1993-1994
69. Evaluation of an intensive intermittent-induction regimen and short course duration of treatment for HIV-related pulmonary tuberculosis
70. Relapse with rifamycin mono-resistant tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and isoniazid
71. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: No activity of isoniazid in the continuation phase
72. 14C-rifabutin in animals and man
73. 14C-rifapentine in healthy volunteers
74. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine, and rifabutin
75. Indinavir (MK 639) drug interactions studies
76. Rifapentine: Its role in the treatment of tuberculosis
77. Ritonavir enables combined therapy with rifampin and saquinavir
78. Rifabutin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy
79. Induction and autoinduction properties of rifamycin derivatives: A review of animal and human studies
80. Autoinduction of rifabutin metabolism in man
81. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers
82. Isolation and identification of major urinary metabolites of rifabutin in rats and humans
83. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents
84. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450: Relevance to clinical interaction with fluconazole
85. Rifampin and rifabutin and their metabolism by human liver esterases
86. CYP 3A proteins are expressed on human neutrophils and lymphocytes bur are not induced by rifampin
87. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes
88. 14C-N-methyl]erythromycin breath test in healthy male volunteers
89. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
90. Pharmacokinetic drug interactions with rifampin
91. The effect of antipyrine and rifampin on the metabolism of diazepam
92. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6
93. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo
94. Pharmacogenetic determination of codeine induction by rifampin: The impact on codeine's respiratory, psychomotor and miotic effects
95. Induction of zidovudine glucuronidation and amination pathways by rifampin in HIV infected patients
96. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
97. Interaction between rifampin and levothyroxine
98. Update on rifampin drug interactions, III
99. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis
100. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin
101. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV- 1 protease inhibitor
102. Pharmacokinetic drug interactions with amprenavir
103. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers
104. Pharmacokinetic interaction of nelfinavir with hall-dose rifabutin
105. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in HIV patients
106. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
107. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors
108. Alteration of ribosomes and RNA polymerase in drug-resistant clinical isolates of Mycobacterium tuberculosis
109. 14C by Mycobacterium tuberculosis
110. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis
111. Understanding the chemotherapy of tuberculosis: Current problems
112. The early bactericidal activity of drugs in patients with pulmonary tuberculosis
113. U.S. Public Health Service trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis
114. Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolates before treatment of patients in Taiwan
115. Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan
116. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis
117. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis
118. Binding of rifampicin by human plasma proteins
119. Uptake of antibiotics by human alveolar macrophages
120. Comparison of activities of rifapentine, and rifampin against Mycobacterium tuberculosis residing in human macrophages
121. Intraphagocytic penetration of antibiotics
122. Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes
123. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages
124. Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods
125. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications
126. A four-year follow-up of patients with quiescent pulmonary tuberculosis at the end of a year of chemotherapy with twice-weekly isoniazid plus streptomycin or daily isoniazid plus PAS
127. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
128. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
129. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
130. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151
131. In vitro effect of alpha1acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors
132. Salivary levels of isoniazid and rifampicin in tuberculosis patients
133. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis
134. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice: Long term effectiveness of 6- and 8-month treatment regimens
135. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: A multinational, randomized, comparative study versus rifampicin
136. Development of rifapentine: The way ahead
137. The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: A critical review
138. Rifampin in initial treatment of pulmonary tuberculosis
139. Hypersensitivity reactions to rifampin: Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions
140. Rifampin-induced immune thrombocytopenia
141. Adverse effects of rifampin
142. Intravascular hemolysis and acute renal failure following intermittent rifampin therapy
143. Acute hemolysis and renal failure following discontinuous use of rifampin
144. A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis
145. A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: Results up to 30 months
146. Rifampin-induced thrombocytopenia
147. Rifampin-associated thrombocytopenia secondary to poor compliance
148. Adverse reaction to rifampicin in antituberculosis regimens
149. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin
150. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease
151. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial
152. Unusual pigmentation in patients with AIDS who are receiving rifabutin for bacteremia due to Mycobacterium avium/Mycobacterium intracellulare complex
153. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia
154. Evaluation of the antiviral effect of rifabutin in AIDS-related complex
155. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium lung disease
156. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events
157. Using therapeutic drug monitoring to dose the antimycobacterial drugs
158. Global surveillance for antituberculosis-drug resistance, 1994-1997
159. Standard short-course chemotherapy for drug-resistant tuberculosis: Treatment outcomes in 6 countries